VNDA (Vanda Pharmaceuticals) FFO


VNDA Vanda Pharmaceuticals Inc VNDA
75 GF Score
Price $5.88
GF Value $5.47
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

VNDA
75GF Score
Vanda Pharmaceuticals Inc VNDA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vanda Pharmaceuticals (VNDA) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of $5.88 is trading 7.4% above its estimated GF Value™ of $5.47. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for VNDA:

  • FFO:
  • GF Value™: $5.47 vs. price of $5.88 (7.4% above fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the VNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Other Exchanges 0LKB:UKVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
75GF Score

Get the complete analysis for VNDA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.88
Price
$5.47
GF Value